Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidemiological risk factors in microscopic colitis: a prospective case-control study.
Fernández-Bañares F, de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Diví V, García-Planella E, Ordás I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; RECOMINA Project, GETECCU Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa. Fernández-Bañares F, et al. Among authors: ordas i. Inflamm Bowel Dis. 2013 Feb;19(2):411-7. doi: 10.1002/ibd.23009. Inflamm Bowel Dis. 2013. PMID: 23344243
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
Arenas A, Moreta MJ, Ordás I, Fernández-Clotet A, Caballol B, Gallego M, Vara A, Barastegui R, Giner A, Prieto C, Masamunt MC, Candia R, Ricart E. Arenas A, et al. Among authors: ordas i. Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00376-X. doi: 10.1016/j.gastrohep.2023.07.005. Online ahead of print. Gastroenterol Hepatol. 2023. PMID: 37562767 English, Spanish.
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
Fernández-Clotet A, Ordás I, Masamunt MC, Caballol B, Rodríguez S, Gallego M, Barastegui R, Saavedra AC, Panés J, Ricart E, Rimola J. Fernández-Clotet A, et al. Among authors: ordas i. Aliment Pharmacol Ther. 2024 Jun;59(11):1435-1445. doi: 10.1111/apt.17968. Epub 2024 Apr 23. Aliment Pharmacol Ther. 2024. PMID: 38650481
Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn's disease patients.
Giordano A, Rovira M, Veny M, Barastegui R, Marín P, Martínez C, Fernández-Avilés F, Suárez-Lledó M, Domènech A, Serrahima A, Lozano M, Cid J, Ordás I, Fernández-Clotet A, Caballol B, Gallego M, Vara A, Masamunt MC, Giner À, Teubel I, Esteller M, Corraliza AM, Panés J, Salas A, Ricart E. Giordano A, et al. Among authors: ordas i. J Crohns Colitis. 2024 May 17:jjae076. doi: 10.1093/ecco-jcc/jjae076. Online ahead of print. J Crohns Colitis. 2024. PMID: 38757210
Impact of mass screening for gluten-sensitive enteropathy in working population.
Mariné M, Fernández-Bañares F, Alsina M, Farré C, Cortijo M, Santaolalla R, Salas A, Tomàs M, Abugattas E, Loras C, Ordás I, Viver JM, Esteve M. Mariné M, et al. Among authors: ordas i. World J Gastroenterol. 2009 Mar 21;15(11):1331-8. doi: 10.3748/wjg.15.1331. World J Gastroenterol. 2009. PMID: 19294762 Free PMC article.
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Loras C, et al. Among authors: ordas i. Gut. 2010 Oct;59(10):1340-6. doi: 10.1136/gut.2010.208413. Epub 2010 Jun 24. Gut. 2010. PMID: 20577000
86 results